Return to homepagePandemic Pact

(Theme 3) Predicting clinical trajectories of disease progression in SARS2-COVID19 on the basis of high-throughput plasma proteomics and maching learning

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-360

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Markus Ralser, Bram Snijders

  • Research Location

    United Kingdom, Germany

  • Lead Research Institution

    Francis Crick Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Analysis of patient blood samples provides information about disease progression and the opportunity to identify new biomarkers and therpeutic targets for COVID-19. However the process of sampling can often be slow. Proteomic high throughput analysis of patient sera will provide additional biomarkers for stratification of patients. In collaboration with the Coronavirus Clinical Characterisation Consortium (ISARIC 4C) at Edinburgh University and the Charite Hospital (Berlin) Crick researchers are developing newly designed high-throughput mass spectrometry-based platforms to obtain unbiased information about disease progression and distinctions between patients with severe and moderate Covid-19 disease.